10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $99,314.10 in Stock

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,087 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $99,314.10. Following the transaction, the insider now directly owns 350,055 shares of the company’s stock, valued at approximately $8,506,336.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

10x Genomics Price Performance

10x Genomics stock opened at $22.59 on Friday. 10x Genomics, Inc. has a 1-year low of $22.50 and a 1-year high of $63.57. The company’s 50-day moving average is $30.74 and its 200 day moving average is $40.78.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). The business had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted ($0.44) earnings per share. On average, equities research analysts anticipate that 10x Genomics, Inc. will post -1.55 EPS for the current year.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors have recently modified their holdings of TXG. Commonwealth Equity Services LLC increased its position in shares of 10x Genomics by 26.0% during the third quarter. Commonwealth Equity Services LLC now owns 7,193 shares of the company’s stock worth $297,000 after acquiring an additional 1,486 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of 10x Genomics during the third quarter valued at approximately $146,000. Principal Financial Group Inc. boosted its stake in shares of 10x Genomics by 4.2% during the third quarter. Principal Financial Group Inc. now owns 23,741 shares of the company’s stock valued at $979,000 after purchasing an additional 948 shares in the last quarter. Larson Financial Group LLC bought a new position in shares of 10x Genomics during the third quarter valued at approximately $362,000. Finally, Jump Financial LLC boosted its stake in shares of 10x Genomics by 320.9% during the third quarter. Jump Financial LLC now owns 73,855 shares of the company’s stock valued at $3,047,000 after purchasing an additional 56,307 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on TXG. The Goldman Sachs Group dropped their price objective on shares of 10x Genomics from $30.00 to $26.00 and set a “sell” rating for the company in a report on Wednesday, May 1st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. TD Cowen cut shares of 10x Genomics from a “buy” rating to a “hold” rating and decreased their target price for the company from $57.00 to $32.00 in a research report on Wednesday, May 1st. Canaccord Genuity Group decreased their target price on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, April 29th. Finally, Barclays decreased their target price on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.